Fifty-four thousand customers. Eighty countries. Five million dollars in proceeds. And a product that, when federal investigators finally tested it, sometimes wasn’t the product at all — it was testosterone, a Schedule III controlled substance, sold under the label of a legal-sounding SARM to people who had no idea what they were actually injecting.
On July 30, 2026, a federal judge in South Bend, Indiana sentenced Matthew J. Kawa, 48, of Grant Park, Illinois, to 70 months in prison. His sister and co-defendant, Jennifer L. Stechkober, 32, of Michigan City, Indiana, received 16 months. Both pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead. Kawa additionally pleaded guilty to illegally importing merchandise into the United States. The company they ran, Paradigm Peptides, is now a case study in exactly what federal prosecutors mean when they say the grey market has a criminal exposure problem, not just a regulatory one.
What Paradigm Peptides Actually Was
According to the U.S. Attorney’s Office for the Northern District of Indiana, Kawa operated Paradigm Peptides as an online storefront selling peptides, Human Chorionic Gonadotropin (HCG), and Selective Androgen Receptor Modulators (SARMs) directly to consumers. Between 2019 and 2024, the business shipped to more than 54,000 customers in all 50 states and more than 80 countries. That is not a fringe operation running out of someone’s garage on a weekend — that is, by the numbers, one of the larger direct-to-consumer research chemical operations that has ever been prosecuted in the United States.
The site’s marketing, per the DOJ’s account, told customers the business was licensed and registered with the FDA, that products were manufactured at its own U.S. laboratories, that everything was tested for quality, and that it was pharmaceutical grade. Prosecutors say every part of that was false. The products were imported from China and India. They were not tested before being sold. And in a detail that should stop anyone currently trusting a peptide label at face value, investigators determined that many products sold as SARMs were not SARMs — they were testosterone, misrepresented on the label of a product being mailed directly to tens of thousands of people who thought they were buying something else entirely.
“They lied to the world at large saying their company was legitimate; their products were safe, pure, tested, and manufactured in the United States; and that they were approved by the FDA. They were all lies.”
— U.S. Attorney Adam L. Mildred, Northern District of Indiana
The Warning Letters Nobody Acted On
Here is the part of the story that deserves the most attention from anyone currently buying from an unfamiliar vendor: the FDA warned Kawa twice, in 2020 and again in 2022, that he was marketing and selling unapproved drugs in violation of the Food, Drug and Cosmetic Act. The business kept operating for two more years after the second letter. A warning letter is not a formality and it is not the end of a story — it is very often the first chapter of one. Vendors who receive them and change nothing are not vendors who “got a slap on the wrist.” They are vendors who made a calculated bet that enforcement would stop at a letter. In this case, it didn’t.
What Happened to the Customers
The human cost here is the part that tends to get skipped in coverage that focuses only on the dollar figures. According to the U.S. Attorney’s statement, customers who unknowingly ingested testosterone that had been mislabeled as a SARM reported skin irritation and chronic acne, drops in natural testosterone severe enough to require testosterone replacement therapy, cardiac health issues, and psychological effects including stress, anxiety, and in some cases suicidal ideation. These are not hypothetical harms cited to make a legal point. They are harms the government says it documented in victims who trusted a label that had already been flagged by federal regulators years earlier.
That is the actual risk profile of buying unverified product from an unverified source: not just “it might not work,” but the product in the vial may not be what the label says it is at all, and you have no reliable way to find out until something goes wrong in your own body.
The Money
The court entered a money judgment against Kawa for $5 million — the government’s estimate of what he derived in illegal proceeds. Both defendants were separately ordered to pay $78,317.52 in restitution to identified victims, a figure that inevitably represents a fraction of the harm done across 54,000 customers, most of whom will never see a dollar back. That gap is worth sitting with: restitution in cases like this is capped by what can be documented and proven for specific victims, not by the true scale of what was taken from a customer base spread across 80 countries.
Who Investigated It
The case was built by the FDA’s Office of Criminal Investigations and the United States Postal Inspection Service, and prosecuted by Assistant U.S. Attorney Luke N. Reilander. FDA Special Agent in Charge Ronne Malham framed the case as a warning to the broader market: evading FDA review and distributing unapproved drugs “poses a serious risk to public health and safety,” and the agency “will continue to investigate and hold accountable those who traffic in unapproved drugs.” That is not boilerplate. Coming after a wave of warning letters, warehouse actions, and now a felony sentence with a five-year custodial term, it reads as a statement of intent about where enforcement priority sits going into the back half of 2026.
What This Case Actually Tells Researchers
Three things stand out from the Paradigm Peptides record that apply well beyond this one company.
Scale is not a safety signal. A business with 54,000 customers, a professional-looking website, and years of operating history is not inherently more trustworthy than a smaller one. Paradigm operated for roughly five years and shipped to 80 countries while, according to prosecutors, selling a controlled substance under a false label the entire time.
Claims of FDA registration and in-house testing mean nothing unless they can be independently verified. Anyone can put “FDA registered” or “third-party tested” on a website. The FDA does not “register” or endorse research peptide vendors, and a testing claim is only as good as the lab behind it — a lab a buyer can actually look up, with a name, a location, and a verifiable track record on the Certificate of Analysis.
A label is not proof of contents. The single most alarming detail in this case for the wider research community is that a product sold and labeled as one compound was, according to federal investigators, frequently a completely different and controlled substance. That is not a purity problem. That is a fundamental failure of the only piece of information a buyer has to go on.
Where This Fits
Paradigm Peptides is not an isolated case — it’s one entry in a growing federal record that includes FDA warning letters against dozens of vendors, the shutdown of long-operating research peptide storefronts, and a Department of Justice that has already secured a felony forfeiture against at least one other compounding operation for unapproved peptide distribution. We’re tracking that broader pattern in our Grey Market Watch hub, alongside the customs and supply-chain side of the story and a plain-language guide to the red flags that show up again and again in community-reported scam cases. If you’re evaluating a vendor right now, our Vendor Guide walks through exactly what a real Certificate of Analysis should contain and what Paradigm’s customers didn’t have.
This article covers public court and regulatory records. It is not legal advice and is not an accusation against any party beyond what has been established in the referenced public record. Nothing in this article should be read as encouraging the purchase or use of unapproved drugs for human consumption.